Shy-Drager Syndrome
A progressive neurodegenerative condition of the central and autonomic nervous systems characterized by atrophy of the preganglionic lateral horn neurons of the thoracic spinal cord. This disease is generally considered a clinical variant of MULTIPLE SYSTEM ATROPHY. Affected individuals present in the fifth or sixth decade with ORTHOSTASIS and bladder dysfunction; and later develop FECAL INCONTINENCE; anhidrosis; ATAXIA; IMPOTENCE; and alterations of tone suggestive of basal ganglia dysfunction. (From Adams et al., Principles of Neurology, 6th ed, p536)
Drugs by status
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (24)
- PPD
- Chelsea Therapeutics
- Aventis
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of London
- German Center for Neurodegenerative Diseases (DZNE)
- German Parkinson Study Group (GPS)
- New York University
- University of Michigan
- Mayo Clinic
- University of Ulm
- Vanderbilt University
- University of Toulouse
- National Taiwan University
- Ludwig Maximilians University
- University of Paris
- Biohaven Pharmaceuticals Inc.
- General Electric
- Deutsche Parkinson Vereinigung
- Deutsche Stiftung Neurologie
- ParkinsonFonds Deutschland gGmbH
- Rare Disease Research Network Autonomic Consortium
- Competence Network on Parkinson's Disease
- European MSA-Study Group
Organization Involved with Phase 2 Indications (13)
Organization Involved with Phase 1 Indications (12)
- Biogen
- Corestem, Inc.
- Affiris AG
- National Heart, Lung, and Blood Institute (NHLBI)
- Harvard University
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Bordeaux
- University of Queensland
- Fundació per a la Recerca Biomedica
- University of Barcelona
- National Center for Advancing Translational Science (NCATS)
- Forschungszentrum Jülich
Organization Involved with Other Experimental Indications (5)